Promising Studies for the Future of Frontline mRCC
Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.
Using TKI/IO Combinations in Patients With mRCC
Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.
Dosing Strategies for Maximum Efficacy With Len + Pembro
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.
Safety Profile of Len + Pembro From CLEAR in mRCC
Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.
CLEAR Trial: Len + Pembro or Everolimus vs Sunitinib
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.
FDA-Approved TKI/IO Combinations in mRCC
Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.
Combining VEGF-TKIs + ICIs in mRCC
Toni Choueiri, MD, focuses on combining VEGF-tyrosine kinase inhibitors with immune checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.
Prevalence of Actionable Biomarkers in Clear-Cell RCC
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, discuss the available biomarkers, predictive biomarkers, and clinical predictors that are currently used in metastatic clear-cell renal cell carcinoma, as well as risk status.
Frontline Treatment of Advanced Renal Cell Carcinoma
The panelists discuss frontline treatment for renal cell carcinoma, highlighting TKIs targeting VEGFR and the mechanisms of action for currently approved therapeutics.
Examining TKI Combinations in Advanced RCC
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
An Analysis of the Phase III ATLAS Trial in RCCâ€‹
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncologyâ€“Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
BPX-201 Vaccine for Chemotherapy-NaÃ¯ve mCRPC
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncologyâ€“Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naÃ¯ve mCRPC.
2 Commerce Drive Cranbury, NJ 08512